Skip to main content
Erschienen in: Acta Diabetologica 3/2011

01.09.2011 | Original Article

Excess mortality in middle-aged men with diabetes aged 15–34 years at diagnosis

verfasst von: Carina Törn, Sofie Ingemansson, Ulf Lindblad, Soffia Gudbjörnsdottir, on behalf of the DISS study group

Erschienen in: Acta Diabetologica | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to assess mortality risk and the excess of risk in patients with diabetes. Patients were 15–34 years old at diagnosis of diabetes mellitus (n = 879) in 1992 and 1993 in this national cohort from Sweden. Healthy controls were matched for gender and birth on the same day as the index cases (n = 837). The civic registration number was used to link patients and controls to the Swedish Cause of Death Registry. During follow-up, 3.3% (29/879) of patients and 1.1% (9/837; P = 0.002) of controls died. The risk for a patient with diabetes to die was almost threefold increased compared with healthy controls; hazard ratio, 2.9 (95% CI 1.4–6.2). This increased risk was significant in men; hazard ratio, 2.8 (95% CI 1.2–6.5). Diabetes as the underlying cause of death accounted for 38% (11/29) of deaths among patients. Most patients, 55% (16/29), died at home, remaining patients in hospital, 28% (8/29), or elsewhere 17% (5/29) compared to controls of whom 33% (3/9; P = 0.45) died at home, 33% (3/9; P = 1.0) in hospital, and 33% (3/9; P = 0.36) elsewhere. Only 55% (16/29) of patients had a specified day of death on death certificates compared to 100% (9/9; P = 0.016) of controls. Adult men with diabetes had an almost threefold increased risk to die within 15 years of diagnosis compared to healthy men. Most middle-aged patients with diabetes died at home and often without a specified date of death recorded.
Literatur
1.
Zurück zum Zitat Wibell L, Nystrom L, Ostman J, Arnqvist H, Blohme G, Lithner F, Littorin B, Sundkvist G (2001) Increased mortality in diabetes during the first 10 years of the disease. A population-based study (DISS) in Swedish adults 15–34 years old at diagnosis. J Intern Med 249:263–270PubMedCrossRef Wibell L, Nystrom L, Ostman J, Arnqvist H, Blohme G, Lithner F, Littorin B, Sundkvist G (2001) Increased mortality in diabetes during the first 10 years of the disease. A population-based study (DISS) in Swedish adults 15–34 years old at diagnosis. J Intern Med 249:263–270PubMedCrossRef
2.
Zurück zum Zitat Dahlquist G, Kallen B (2005) Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 28:2384–2387PubMedCrossRef Dahlquist G, Kallen B (2005) Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 28:2384–2387PubMedCrossRef
3.
Zurück zum Zitat Waernbaum I, Blohme G, Ostman J, Sundkvist G, Eriksson JW, Arnqvist HJ, Bolinder J, Nystrom L (2006) Excess mortality in incident cases of diabetes mellitus aged 15-34 years at diagnosis: a population-based study (DISS) in Sweden. Diabetologia 49:653–659PubMedCrossRef Waernbaum I, Blohme G, Ostman J, Sundkvist G, Eriksson JW, Arnqvist HJ, Bolinder J, Nystrom L (2006) Excess mortality in incident cases of diabetes mellitus aged 15-34 years at diagnosis: a population-based study (DISS) in Sweden. Diabetologia 49:653–659PubMedCrossRef
4.
Zurück zum Zitat Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G (2006) Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 49:298–305PubMedCrossRef Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G (2006) Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 49:298–305PubMedCrossRef
5.
Zurück zum Zitat Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J, Schober E, Gyurus E, Castell C, Urbonaite B, Rosenbauer J, Iotova V, Thorsson AV, Soltesz G (2007) Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. Diabetologia 50:2439–2442PubMedCrossRef Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J, Schober E, Gyurus E, Castell C, Urbonaite B, Rosenbauer J, Iotova V, Thorsson AV, Soltesz G (2007) Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. Diabetologia 50:2439–2442PubMedCrossRef
6.
Zurück zum Zitat Asao K, Sarti C, Forsen T, Hyttinen V, Nishimura R, Matsushima M, Reunanen A, Tuomilehto J, Tajima N (2003) Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland. Diabetes Care 26:2037–2042PubMedCrossRef Asao K, Sarti C, Forsen T, Hyttinen V, Nishimura R, Matsushima M, Reunanen A, Tuomilehto J, Tajima N (2003) Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland. Diabetes Care 26:2037–2042PubMedCrossRef
7.
Zurück zum Zitat Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC (2003) Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 46:760–765PubMedCrossRef Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC (2003) Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 46:760–765PubMedCrossRef
8.
Zurück zum Zitat Green A, Borch-Johnsen K, Andersen PK, Hougaard P, Keiding N, Kreiner S, Deckert T (1985) Relative mortality of type 1 (insulin-dependent) diabetes in Denmark: 1933–1981. Diabetologia 28:339–342PubMedCrossRef Green A, Borch-Johnsen K, Andersen PK, Hougaard P, Keiding N, Kreiner S, Deckert T (1985) Relative mortality of type 1 (insulin-dependent) diabetes in Denmark: 1933–1981. Diabetologia 28:339–342PubMedCrossRef
9.
Zurück zum Zitat Sartor G, Nystrom L, Dahlquist G (1991) The Swedish Childhood Diabetes Study: a seven-fold decrease in short-term mortality? Diabet Med 8:18–21PubMedCrossRef Sartor G, Nystrom L, Dahlquist G (1991) The Swedish Childhood Diabetes Study: a seven-fold decrease in short-term mortality? Diabet Med 8:18–21PubMedCrossRef
10.
Zurück zum Zitat Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J (2000) Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619–4623PubMedCrossRef Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J (2000) Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619–4623PubMedCrossRef
11.
Zurück zum Zitat Torn C, Landin-Olsson M, Ostman J, Schersten B, Arnqvist H, Blohme G, Bjork E, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G, Lernmark A (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16:442–447PubMedCrossRef Torn C, Landin-Olsson M, Ostman J, Schersten B, Arnqvist H, Blohme G, Bjork E, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G, Lernmark A (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16:442–447PubMedCrossRef
12.
Zurück zum Zitat Torn C, Landin-Olsson M, Lernmark A, Schersten B, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G (2001) Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 33:115–120PubMedCrossRef Torn C, Landin-Olsson M, Lernmark A, Schersten B, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G (2001) Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 33:115–120PubMedCrossRef
13.
Zurück zum Zitat Diabetes Mellitus (1985) Report of a WHO study group. Technical report series No 727, Geneva. Diabetes Mellitus (1985) Report of a WHO study group. Technical report series No 727, Geneva.
14.
Zurück zum Zitat Littorin B, Sundkvist G, Schersten B, Nystrom L, Arnqvist HJ, Blohme G, Lithner F, Wibell L, Ostman J (1996) Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS). Diabetes Res Clin Pract 33:129–133PubMedCrossRef Littorin B, Sundkvist G, Schersten B, Nystrom L, Arnqvist HJ, Blohme G, Lithner F, Wibell L, Ostman J (1996) Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS). Diabetes Res Clin Pract 33:129–133PubMedCrossRef
15.
Zurück zum Zitat Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia 49:660–666PubMedCrossRef Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia 49:660–666PubMedCrossRef
16.
Zurück zum Zitat Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH (2008) Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 31:1360–1366PubMedCrossRef Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH (2008) Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 31:1360–1366PubMedCrossRef
17.
Zurück zum Zitat Tu E, Twigg SM, Duflou J, Semsarian C (2008) Causes of death in young Australians with type 1 diabetes: a review of coronial post-mortem examinations. Med J Aust 188:699–702PubMed Tu E, Twigg SM, Duflou J, Semsarian C (2008) Causes of death in young Australians with type 1 diabetes: a review of coronial post-mortem examinations. Med J Aust 188:699–702PubMed
18.
Zurück zum Zitat Ostgren CJ, Lindblad U, Melander A, Rastam L (2002) Survival in patients with type 2 diabetes in a Swedish community: Skaraborg hypertension and diabetes project. Diabetes Care 25:1297–1302PubMedCrossRef Ostgren CJ, Lindblad U, Melander A, Rastam L (2002) Survival in patients with type 2 diabetes in a Swedish community: Skaraborg hypertension and diabetes project. Diabetes Care 25:1297–1302PubMedCrossRef
19.
Zurück zum Zitat Grauslund J, Jorgensen TM, Nybo M, Green A, Rasmussen LM, Sjolie AK (2009) Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes. J Diabetes Complicat 24:223–228PubMedCrossRef Grauslund J, Jorgensen TM, Nybo M, Green A, Rasmussen LM, Sjolie AK (2009) Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes. J Diabetes Complicat 24:223–228PubMedCrossRef
20.
Zurück zum Zitat Krishnan S, Short KR (2009) Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes. J Cardiometab Syndr 4:50–56PubMedCrossRef Krishnan S, Short KR (2009) Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes. J Cardiometab Syndr 4:50–56PubMedCrossRef
21.
Zurück zum Zitat Futh R, Dinh W, Bansemir L, Ziegler G, Bufe A, Wolfertz J, Scheffold T, Lankisch M (2009) Newly detected glucose disturbance is associated with a high prevalence of diastolic dysfunction: double risk for the development of heart failure? Acta Diabetol 46:335–338PubMedCrossRef Futh R, Dinh W, Bansemir L, Ziegler G, Bufe A, Wolfertz J, Scheffold T, Lankisch M (2009) Newly detected glucose disturbance is associated with a high prevalence of diastolic dysfunction: double risk for the development of heart failure? Acta Diabetol 46:335–338PubMedCrossRef
22.
Zurück zum Zitat Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145–154PubMedCrossRef Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145–154PubMedCrossRef
23.
Zurück zum Zitat Wit MA, de Mulder M, Jansen EK, Umans VA (2010) Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery. Acta Diabetol [Epub ahead of print] PubMed PMID: 20857149 Wit MA, de Mulder M, Jansen EK, Umans VA (2010) Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery. Acta Diabetol [Epub ahead of print] PubMed PMID: 20857149
24.
Zurück zum Zitat May O, Arildsen H (2011) Long-term predictive power of heart rate variability on all-cause mortality in the diabetic population. Acta Diabetol 48:55–59 May O, Arildsen H (2011) Long-term predictive power of heart rate variability on all-cause mortality in the diabetic population. Acta Diabetol 48:55–59
25.
Zurück zum Zitat Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47:87–95PubMedCrossRef Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47:87–95PubMedCrossRef
26.
Zurück zum Zitat Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D’Alfonso R, Perna M, Lauro D, Federici M, Gambardella S, Lauro R, Sesti G (2003) The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 88:3368–3371PubMedCrossRef Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D’Alfonso R, Perna M, Lauro D, Federici M, Gambardella S, Lauro R, Sesti G (2003) The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 88:3368–3371PubMedCrossRef
27.
Zurück zum Zitat Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D’Alfonso R, Patera I, Cappa M, Nistico L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R (2003) The Gly972– > Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes 52:887–890PubMedCrossRef Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D’Alfonso R, Patera I, Cappa M, Nistico L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R (2003) The Gly972– > Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes 52:887–890PubMedCrossRef
28.
Zurück zum Zitat Perticone F, Sciacqua A, Scozzafava A, Ventura G, Laratta E, Pujia A, Federici M, Lauro R, Sesti G (2004) Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 89:3606–3609PubMedCrossRef Perticone F, Sciacqua A, Scozzafava A, Ventura G, Laratta E, Pujia A, Federici M, Lauro R, Sesti G (2004) Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 89:3606–3609PubMedCrossRef
29.
Zurück zum Zitat Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone F, Lauro R (2004) The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27:1394–1398PubMedCrossRef Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone F, Lauro R (2004) The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27:1394–1398PubMedCrossRef
30.
Zurück zum Zitat Chida Y, Hamer M (2008) An association of adverse psychosocial factors with diabetes mellitus: a meta-analytic review of longitudinal cohort studies. Diabetologia 51:2168–2178PubMedCrossRef Chida Y, Hamer M (2008) An association of adverse psychosocial factors with diabetes mellitus: a meta-analytic review of longitudinal cohort studies. Diabetologia 51:2168–2178PubMedCrossRef
31.
Zurück zum Zitat Helgeson VS, Reynolds KA, Escobar O, Siminerio L, Becker D (2007) The role of friendship in the lives of male and female adolescents: does diabetes make a difference? J Adolesc Health 40:36–43PubMedCrossRef Helgeson VS, Reynolds KA, Escobar O, Siminerio L, Becker D (2007) The role of friendship in the lives of male and female adolescents: does diabetes make a difference? J Adolesc Health 40:36–43PubMedCrossRef
32.
Zurück zum Zitat Littorin B, Sundkvist G, Nystrom L, Carlson A, Landin-Olsson M, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson JW, Schersten B, Wibell L (2001) Family characteristics and life events before the onset of autoimmune type 1 diabetes in young adults: a nationwide study. Diabetes Care 24:1033–1037PubMedCrossRef Littorin B, Sundkvist G, Nystrom L, Carlson A, Landin-Olsson M, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson JW, Schersten B, Wibell L (2001) Family characteristics and life events before the onset of autoimmune type 1 diabetes in young adults: a nationwide study. Diabetes Care 24:1033–1037PubMedCrossRef
33.
Zurück zum Zitat Tattersall RB, Gill GV (1991) Unexplained deaths of type 1 diabetic patients. Diabet Med 8:49–58PubMedCrossRef Tattersall RB, Gill GV (1991) Unexplained deaths of type 1 diabetic patients. Diabet Med 8:49–58PubMedCrossRef
34.
Zurück zum Zitat Sartor G, Dahlquist G (1995) Short-term mortality in childhood onset insulin-dependent diabetes mellitus: a high frequency of unexpected deaths in bed. Diabet Med 12:607–611PubMedCrossRef Sartor G, Dahlquist G (1995) Short-term mortality in childhood onset insulin-dependent diabetes mellitus: a high frequency of unexpected deaths in bed. Diabet Med 12:607–611PubMedCrossRef
Metadaten
Titel
Excess mortality in middle-aged men with diabetes aged 15–34 years at diagnosis
verfasst von
Carina Törn
Sofie Ingemansson
Ulf Lindblad
Soffia Gudbjörnsdottir
on behalf of the DISS study group
Publikationsdatum
01.09.2011
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 3/2011
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0272-2

Weitere Artikel der Ausgabe 3/2011

Acta Diabetologica 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.